Jane Street Group LLC Purchases 28,486 Shares of DURECT Co. (NASDAQ:DRRX)

Jane Street Group LLC boosted its stake in DURECT Co. (NASDAQ:DRRX) by 266.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,196 shares of the specialty pharmaceutical company’s stock after purchasing an additional 28,486 shares during the quarter. Jane Street Group LLC owned approximately 0.13% of DURECT worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Richmond Brothers Inc. raised its holdings in shares of DURECT by 12.2% during the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after buying an additional 138,920 shares in the last quarter. Institutional investors own 28.03% of the company’s stock.

Wall Street Analyst Weigh In

DRRX has been the topic of a number of recent analyst reports. Wall Street Zen assumed coverage on DURECT in a research report on Thursday, May 22nd. They issued a “sell” rating on the stock. HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, March 27th.

DURECT Trading Up 2.2%

Shares of DURECT stock opened at $0.55 on Tuesday. DURECT Co. has a 12 month low of $0.48 and a 12 month high of $1.84. The stock has a 50 day moving average of $0.65 and a 200 day moving average of $0.76. The firm has a market cap of $17.16 million, a PE ratio of -0.91 and a beta of 0.59.

DURECT (NASDAQ:DRRX) last released its quarterly earnings data on Wednesday, March 26th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.12). The firm had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $6.91 million. DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%. As a group, equities research analysts forecast that DURECT Co. will post -0.5 earnings per share for the current fiscal year.

DURECT Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.